세계의 전신 마취제 시장 보고서(2025년)
General Anesthesia Drugs Global Market Report 2025
상품코드 : 1751006
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전신 마취제 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에는 CAGR 3.9%를 나타내 60억 8,000만 달러로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 디지털 건강 솔루션에 대한 관심 증가, 수술 증가, 세계 인구 증가, 심혈관 질환의 유병률 증가, 고도 모니터링 시스템에 대한 투자 증가로 인한 것으로 예측됩니다. 예측기간에 예상되는 주요 동향으로는 의료기술의 발전, 신규 약제제제의 개발, 마취 전달에 있어서의 로봇 공학의 통합, 약제 분자의 혁신, 마취 관련 기술의 현저한 진보 등이 있습니다.

수술 증가는 전신 마취제 시장 확대를 견인할 것으로 예측됩니다. 수술은 숙련된 전문가가 질병, 부상, 이상을 치료하기 위해 수행하는 의료 행위이며 일반적으로 내부 구조에 접근하기 위해 절개하거나 특수기구를 사용해야 합니다. 외과적 치료의 급증은 만성 질환의 유병률 증가로 인한 것이 크며, 대부분은 효과적인 치료를 위해 수술적 개입이 필요합니다. 전신 마취제는 이러한 수술에서 의식불명을 유발하고 통증을 없애줌으로써 환자가 복잡한 수술이나 침습적인 수술 중에 움직이지 않고 의식불명으로 있을 수 있도록 하는 중요한 역할을 담당하고 있습니다. 예를 들어 2024년 6월 미국을 기반으로 하는 최소 침습 수술을 감독하는 비영리 단체인 미국 성형외과학회는 2023년 중 수술 건수가 2022년 2% 증가에서 7% 증가했다고 보고했습니다. 그 결과, 수술의 빈도 증가가 전신 마취제 시장 성장에 박차를 가하고 있습니다.

전신 마취제 시장의 주요 기업은 환자의 안전성을 높이고, 회복 시간을 빨리, 수술 효율을 높이는 단시간 작용형 벤조디아제핀 등의 혁신적인 솔루션의 개발에 주력하고 있습니다. 이와 같은 단시간 작용형 벤조디아제핀은 즉효성과 작용 시간의 단기 때문에 수술에 의한 진정을 위해 일반적으로 사용되고 있습니다. 예를 들어, 2023년 8월 독일에 본사를 둔 생명공학 회사인 PAION AG는 네덜란드에서 전신 마취용 바이파보(성분명 레미마졸람)를 출시하여 유럽에서 상업적 데뷔를 했습니다. 바이파보는 1-1.5분 이내에 효과가 나타나고 11-14분 이내에 회복되므로 단시간 수술에 이상적입니다. 주로 시토크롬 P450 간 경로가 아닌 몸 전체에 널리 분포된 간 에스테라아제 효소에 의해 대사됩니다. 바이파보는 다른 벤조디아제핀계 마취제과 같이, 필요에 따라서 진정 작용을 신속하게 상쇄할 수 있는 풀마제닐이라고 하는 역전제를 가지고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

General anesthesia drugs are pharmacological agents that induce a controlled, reversible state of unconsciousness, analgesia, and immobility during surgical or medical procedures. These drugs work by depressing the central nervous system to prevent pain perception and the formation of memories related to the procedure. They are typically administered intravenously or via inhalation and are carefully adjusted to achieve the desired depth of anesthesia, ensuring patient safety and comfort throughout the operation.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main general anesthesia drugs include sevoflurane, propofol, dexmedetomidine, remifentanil, desflurane, midazolam, and other medications. Sevoflurane, a volatile anesthetic, is commonly used to both induce and maintain general anesthesia during surgical procedures. It can be administered intravenously or through inhalation and is applied in a variety of surgeries, including cardiovascular, orthopedic, neurosurgery, general, cosmetic, and others. This drug is used by a range of end-users, including hospitals, ambulatory surgical centers, clinics, and other healthcare facilities.

The general anesthesia drugs market research report is one of a series of new reports from The Business Research Company that provides general anesthesia drugs market statistics, including the general anesthesia drugs industry global market size, regional shares, competitors with the general anesthesia drugs market share, detailed general anesthesia drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the general anesthesia drugs industry. This general anesthesia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The general anesthesia drugs market size has grown steadily in recent years. It will grow from $5.01 billion in 2024 to $5.22 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth during the historic period can be attributed to the growing preference for ambulatory surgical centers (ASCs), an increasing number of emergency and trauma cases, advancements in drug formulations, rising demand for customized anesthetic solutions, and the growing prevalence of cosmetic and elective surgeries.

The general anesthesia drugs market size is expected to see steady growth in the next few years. It will grow to $6.08 billion in 2029 at a compound annual growth rate (CAGR) of 3.9%. The growth during the forecast period can be attributed to a heightened focus on digital health solutions, an increase in surgical procedures, a rising global population, a growing prevalence of cardiovascular diseases, and increased investments in advanced monitoring systems. Key trends expected in the forecast period include advancements in medical technology, the development of novel drug formulations, the integration of robotics in anesthesia delivery, innovation in drug molecules, and significant progress in anesthesia-related technologies.

The growing number of surgical procedures is expected to drive the expansion of the general anesthesia drugs market. Surgical procedures involve medical operations conducted by skilled professionals to treat diseases, injuries, or abnormalities, typically requiring incisions or the use of specialized instruments to access internal structures. The surge in surgical procedures is largely attributed to the rising prevalence of chronic diseases, many of which necessitate surgical intervention for effective treatment. General anesthesia drugs play a crucial role in these procedures by inducing unconsciousness and eliminating pain, ensuring that patients remain immobile and unaware throughout complex or invasive surgeries. For example, in June 2024, the American Society of Plastic Surgeons, a US-based nonprofit overseeing minimally invasive procedures, reported a 7% increase in procedures during 2023-up from a 2% increase in 2022. As a result, the increasing frequency of surgical procedures is fueling the growth of the general anesthesia drugs market.

Leading companies in the general anesthesia drugs market are focusing on developing innovative solutions such as short-acting benzodiazepines to enhance patient safety, accelerate recovery times, and boost surgical efficiency. Short-acting benzodiazepines, such as midazolam, are commonly used for procedural sedation due to their rapid onset and short duration of action. For instance, in August 2023, PAION AG, a biotechnology company based in Germany, launched Byfavo (remimazolam) for general anesthesia in the Netherlands, marking its European commercial debut. Byfavo features a quick onset of effects within 1 to 1.5 minutes and recovery within 11 to 14 minutes, making it ideal for short-duration surgeries. It is primarily metabolized by hepatic esterases enzymes widely distributed throughout the body rather than the cytochrome P450 liver pathway. such as other benzodiazepines, Byfavo has a reversal agent, flumazenil, which can quickly counteract its sedative effects if necessary.

In January 2022, Dechra Pharmaceuticals Plc, a UK-based veterinary pharmaceutical company, acquired Isoflurane, USP Inhalant Anesthetic, and Sevoflurane, USP Inhalant Anesthetic from Halocarbon for an undisclosed sum. These products are widely used in veterinary hospitals and enhance Dechra's existing portfolio of sedatives and anesthetics. This acquisition strengthens the company's presence in the veterinary surgical and anesthesia space by providing high-quality, essential anesthetic solutions to the veterinary market. Halocarbon is a US-based manufacturer specializing in general anesthesia drugs.

Major players in the general anesthesia drugs market are Pfizer Inc., Johnson and Johnson Services Inc, AbbVie Inc., GlaxoSmithKline Plc, Boehringer Ingelheim, Mylan NV., Baxter International Inc., Fresenius Kabi USA LLC, Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Aspen Global Incorporated, B. Braun SE, Claris Lifesciences Limited, Avet Pharmaceuticals Inc., Piramal Critical Care, Safeline Pharmaceuticals (Pty) Ltd, Sini Pharma Pvt Ltd., Rouzel Pharma Pvt Ltd.

North America was the largest region in the general anesthesia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in general anesthesia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the general anesthesia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The general anesthesia drugs market consists of sales of neuromuscular blocking agents, opioid analgesics, anesthesia adjuncts and reversal agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

General Anesthesia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on general anesthesia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for general anesthesia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The general anesthesia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. General Anesthesia Drugs Market Characteristics

3. General Anesthesia Drugs Market Trends And Strategies

4. General Anesthesia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global General Anesthesia Drugs Growth Analysis And Strategic Analysis Framework

6. General Anesthesia Drugs Market Segmentation

7. General Anesthesia Drugs Market Regional And Country Analysis

8. Asia-Pacific General Anesthesia Drugs Market

9. China General Anesthesia Drugs Market

10. India General Anesthesia Drugs Market

11. Japan General Anesthesia Drugs Market

12. Australia General Anesthesia Drugs Market

13. Indonesia General Anesthesia Drugs Market

14. South Korea General Anesthesia Drugs Market

15. Western Europe General Anesthesia Drugs Market

16. UK General Anesthesia Drugs Market

17. Germany General Anesthesia Drugs Market

18. France General Anesthesia Drugs Market

19. Italy General Anesthesia Drugs Market

20. Spain General Anesthesia Drugs Market

21. Eastern Europe General Anesthesia Drugs Market

22. Russia General Anesthesia Drugs Market

23. North America General Anesthesia Drugs Market

24. USA General Anesthesia Drugs Market

25. Canada General Anesthesia Drugs Market

26. South America General Anesthesia Drugs Market

27. Brazil General Anesthesia Drugs Market

28. Middle East General Anesthesia Drugs Market

29. Africa General Anesthesia Drugs Market

30. General Anesthesia Drugs Market Competitive Landscape And Company Profiles

31. General Anesthesia Drugs Market Other Major And Innovative Companies

32. Global General Anesthesia Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The General Anesthesia Drugs Market

34. Recent Developments In The General Anesthesia Drugs Market

35. General Anesthesia Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기